Cyclosporin A - A review on fermentative production, downstream processing and pharmacological applications

Biotechnology Advances

Volumn 29, Issue 4, 2011, Pages 418-435

  Survase, Shrikant A ^a   Kagliwal, Lalit D ^a   Annapure, Uday S ^a   Singhal, Rekha S ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Cyclosporin A; Fermentation; Immunosuppressants; Tolypocladium inflatum

Indexed keywords

ANTI-FUNGAL; ANTI-INFLAMMATORIES; BIOLOGICAL ACTIVITIES; BIOSYNTHETIC PATHWAY; CYCLOSPORIN A; DOWNSTREAM-PROCESSING; FERMENTATION TECHNIQUES; FERMENTATIVE PRODUCTION; IMMUNOSUPPRESSANTS; PHARMACOLOGICAL ACTIVITY; TOLYPOCLADIUM INFLATUM; UNDECAPEPTIDE; WORLD MARKET;

INTERNATIONAL TRADE;

FERMENTATION;

CYCLOSPORIN;

ANTIMICROBIAL ACTIVITY; BIOACTIVITY; BIOTECHNOLOGY; DRUG; FERMENTATION; FUNGUS; IMMUNOASSAY; PARASITE; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL; BIOTECHNOLOGY; CHEMISTRY; DRUG EFFECT; DRUG INTERACTION; FERMENTATION; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; REVIEW; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; BIOTECHNOLOGY; CYCLOSPORINE; DRUG INTERACTIONS; FERMENTATION; HUMANS; MOLECULAR SEQUENCE DATA; STRUCTURE-ACTIVITY RELATIONSHIP;

TOLYPOCLADIUM INFLATUM;

EID: 79955595804     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2011.03.004     Document Type: Review

References (289)

1. Aarnio T.H., Agathos S.N. Production of extracellular enzymes and cyclosporin by Tolypocladium inflatum and morphologically related fungi. Biotechnol Lett 1989, 11(11):759-764.
2. Aarnio T.H., Agathos S.N. Pigmented variants of Tolypocladium inflatum in relation to cyclosporin A production. Appl Microbiol Biotechnol 1990, 33(4):435-437.
3. Abbott S., Achener P., Simpson R., Klink F. Effect of radial thermal gradients in elevated temperature high performance liquid chromatography. J Chromatogr 1981, 218:123-135.
4. Abdel-Fattah Y.R., El Enshasy H., Anwar M., Omar H., Abolmagd E., Abou Zahra R. Application of factorial experimental designs for optimization of cyclosporin A production by Tolypocladium inflatum in submerged culture. J Microbiol Biotechnol 2007, 17(12):1930-1936.
5. Adinolfi L.E., Bonventre P.F. Cyclosporin A treatment converts Leishmania donovani-infected C57BL/10 (curing) mice to a non-curing phenotype. Infect Immun 1990, 58:3151-3153.
6. Agathos S.N., Lee J. Mathematical modeling of the production of cyclosporin A by Tolypocladium inflatum: effect of L-valine. Biotechnol Progr 1993, 9(1):54-63.
7. Agathos S.N., Parekh R. Enhancement of cyclosporin production in a Tolypocladium inflatum strain after epichlorohydrin treatment. J Biotechnol 1990, 13(1):73-81.
8. Agathos S.N., Marshall J.W., Maraiti C., Parekh R., Moshosing C. Physiological and genetic factors for process development of cyclosporin A fermentation. J Ind Microbiol 1986, 1:39-48.
9. Agathos S.N., Madhosingh C., Marshall J.W., Lee J. The fungal production of cyclosporine. Ann NY Acad Sci 1987, 506:657-662.
10. Alexander A.G., Barnes N.C., Kay A.B., Corrigan C.J. Clinical response to cyclosporin in chronic severe asthma is associated with reduction in serum soluble interleukin-2 receptor concentrations. Eur Respir J 1995, 8:574-578.
11. Alter M.J. Epidemiology of hepatitis C. Hepatology 1997, 26:62S-65S.
12. Altman R.D., Perez G.O., Sfakianakis G.N. Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med 1992, 93(4):396-402.
13. Armson A., Cunningham G.A., Grubb W.B., Mendis A.H.W. Murin strongyloidiasis: the effects of cyclosporin A and thiabendazole administered singly and in combination. Int J Parasitol 1995, 25:533-535.
14. Bach J.F. Cyclosporine in insulin-dependent diabetes mellitus. J Pediatr 1987, 111(6):1073-1074.
15. Bakhtiari M.R., Moazami N., Fallahpour M., Mirdamadi S., Tabatabaee M., Norouzian D., et al. Production and purification of cyclosporin A from fermentation broth of Tolypocladium inflatum. Sci Iranica 2003, 10(3):367-371.
16. Bakhtiari M.R., Fallahpour M., Foruzanfakhr P., Moazami N. Protoplast fusion technique in Tolypocladium inflatum for increasing cyclosporine production. J Biotechnol 2007, 131(2):S135-S136.
17. Balakrishnan K., Pandey A. The panorama of cyclosporine research. J Basic Microbiol 1996, 36(2):121-147.
18. Balakrishnan K., Pandey A. Growth and cyclosporin A production by an indigenously isolated strain of Tolypocladium inflatum. Folia Microbiol 1996, 41(5):401-406.
19. Balakrishnan K., Pandey A. Influence of amino acids on the biosynthesis of cyclosporin A by Tolypocladium inflatum. Appl Microbiol Biotechnol 1996, 45:800-803.
20. Balaraman K., Mathew N. Optimization of media composition for the production of cyclosporin A by Tolypocladium species. Indian J Med Res 2006, 123:525-530.
21. Balaraman K., Kuppusamy M., George N., Anandkumar K., Sekar C. Evaluation of cyclosporine-A obtained from Tolypocladium sp. for immunosuppressive potential. Indian J Med Res 1991, 94:304-306.
22. Barton C.H., Vaziri N.D., Mina A.S., Crosby S., Seo M.I. Effects of cyclosporine A on magnesium metabolism in rats. J Lab Clin Med 1989, 114:232-236.
23. Beacco E., Bianchi M.L., Minghetti A., Spalla C. Directed biosynthesis of analogues of ergot peptide alkaloids with Claviceps purpurea. Experientia 1978, 34(10):1291-1293.
24. Behal V. Mode of action of microbial bioactive metabolites. Folia Microbiol 2006, 51(5):359-369.
25. Behforouz N.C., Wenger C.D., Mathison B.A. Prophylactic treatment of BALB/c mice with cyclosporine A and its analog B-549 enhances resistance to Leishmnania major. J Immunol 1986, 136:3067-3075.
26. Bell A., Wernli B., Franklin R.M. Roles of peptidyl-prolyl CIS-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporine A, FK506, and rapamycin. Biochem Pharmacol 1994, 48:495-503.
27. Bell A., Roberts H.C., Chappell L.H. The antiparasite effects of cyclosporin A: possible drug targets and clinical applications. Gen Pharmacol 1996, 27(6):963-971.
28. Benchapattarapong N., Anderson W.A., Bai F., Moo-Young M. Rheology and hydrodynamic properties of Tolypocladium inflatum fermentation broth and its simulation. Biopro Biosys Eng 2005, 27:239-247.
29. Benediktsson H., Chea R., Davidoff A., Paul L.C. Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Transplantation 1996, 62:1634-1642.
30. BenEzra D., Matamoros N., Cohen E. Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops. Transplant Proc 1988, 20(2):644-649.
31. Bern M.M., Roberts M.S., Yoburn D. Cyclosporin treatment for aplastic anemia: a case report demonstrating a second response to second exposure to cyclosporin. Am J Hematol 1986, 24(3):307-309.
32. Beveridge T. Cyclosporin-A: an evaluation of clinical results. Transplant Proc 1983, 15:433-437.
33. Beveridge T. Clinical transplantation - overview. Prog Allergy 1986, 38:269-292.
34. Bibikova M.V., Rybakova A.M., Spiridonova I.A., Zhukov V.G., Telesnina G.N. Effect of H-ATPase stimulators on cyclosporin biosynthesis. Antibiot Khimioter 1994, 39(4):8-11.
35. Billich A., Zocher R. Enzymatic synthesis of cyclosporin A. J Biol Chem 1987, 262:17258-17259.
36. Binder A.I., Graham E.M., Sanders M.D., Dinning W., James D.G., Denman A.M. Cyclosporin a in the treatment of severe Behqet's uveitis. Br J Dermatol 1987, 26(4):285-291.
37. Bleik J.H., Tabbara K.F. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991, 98:1679-1684.
38. Bonifacio F.N., Giocanti M., Reynier J.P., Lacarelle B. Nicolay development and validation of HPLC method for the determination of cyclosporin A and its impurities in Neoral® capsules and its generic versions. J Pharm Biomed Anal 2009, 49:540-546.
39. Bonifati D.M., Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol 1997, 244(9):542-547.
40. Borel J.F. Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. Immunology 1976, 31:631-641.
41. Borel J.F. From our laboratories: cyclosporin A. Triangle 1981, 20:97-105.
42. Borel J.F. Cyclosporine: historical perspectives. Cyclosporin biological activity and clinical applications 1983, 3-13. Grune and Stratton Inc., Orlando, Florida. B.D. Kahan (Ed.).
43. Borel J.F., Feurer C., Gubler H.U., Steahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976, 6:468-475.
44. Borel J.F., Feurer C., Magnee C., Steahlin H. Effects of the new anti-lymphocitic peptide cyclosporin A in animals. Immunology 1977, 32:1017-1025.
45. Borel J.F., Baumann G., Beveridge T. Cyclosporine. Encyclopedia of Immunology 1998, Vol. 2:686-689. Elsevier publication. I. Roitt, P. Delves (Eds.).
46. Bout D., Deslee D., Capron A. Antischistosomal effect of cyclosporin A cure and prevention of mouse and rat Schistosoma mansoni. Infect Immun 1986, 52:823-827.
47. The Merck Index: an encyclopedia of chemicals, drugs and biologicals 1996, 1498. Merck & Company, Inc., Whitehouse Station, NJ. 12th edition. S.M. Budavari, J. O'Neal, A. Smith, P.E. Heckelman (Eds.).
48. Bueding E., Hawkins J., Cha Y.N. Antischistosomal effects of cyclosporin A. Agents Actions 1981, 11:380-383.
49. Bullough D.A., Jackson C.G., Henderson P.J.F., Beechey R.B., Linnett P.E. The isolation and purification of the elvapeptins: a family of peptide inhibitors of mitochondrial ATPase activity. FEBS Lett 1982, 145:258-262.
50. Castello L., Sainaghi P.P., Bergamasco L., Letizia C., Bartoli E. Pathways of glomerular toxicity of cyclosporine-A: an "in vitro" study. J Physiol Pharmacol 2005, 56(4):649-660.
51. Chappell L.H., Wastling J.M. Cyclospotin A: anti-parasite drug, modulator of the host-parasite relationship and immunosuppressant. Parasitology 1992, 105(Suppl):S25-S40.
52. Chappell L.H., Thomson A.W., Barker G.C., Smith S.W.G. Dosage timing and route of administration of cyclosporin A and nonimmunosuppressive derivatives of dihydrocyclosporin A and cyclosporine C against Schistosoma mansoni in vivo and in vitro. Antimicrob Agents Chemother 1987, 31:1567-1571.
53. Cheyron D.D., Debruyne D., Lobbedez T., Richer C., Ryckelynck J.P., de Ligny B.H. Effect of sulfasalazine on cyclosporin blood concentration. Eur J Clin Pharmacol 1999, 55(3):227-228.
54. Christians U., Sewing K.F. Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 1995, 28(6):547-559.
55. Christians U., Jacobsen W., Florence S.C. Metabolism and drug interaction of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?. Pharmacol Ther 1998, 80:1-34.
56. Chun G.T., Agathos S.N. Immobilization of Tolypocladium inflatum spores into porous celite beads for cyclosporin A production. J Biotechnol 1989, 9:237-254.
57. Chun G.T., Agathos S.N. Comparative studies of physiological and environmental effects on the production of cyclosporin A in suspended and immobilized cells of T. inflatum. Biotechnol Bioeng 1991, 37:256-265.
58. Chun G.T., Agathos S.N. Dynamic response of immobilized cells to pulse addition of l-valine in cyclosporin A biosynthesis. J Biotechnol 1993, 27(3):283-294.
59. Chun G.T., Agathos S.N. Application of oxygen uptake rate measured by a dynamic method for analysis of related fermentation parameters in cyclosporin A fermentation: suspended and immobilized cell cultures. J Microbiol Biotechnol 2001, 11(6):1055-1060.
60. Colebrook A.L., Jenkins D.D., Lightowlers M.W. Anti-parasitic effect of cyclosporin A on Echinococcus granulosus and characterization of the associated cyclophilin protein. Parasitology 2002, 125(5):485-493.
61. Cordes F., Kaiser R., Selbig J. Bioinformatics approach to predicting HIV drug resistance. Exp Rev Mole Diag 2006, 6:207-215.
62. Craddock G.N., Nordgren S.R., Reznick R.K., Gilas T., Lossing A.G., Cohen Z., et al. Small bowel transplantation in the dog using cyclosporine. Transplantation 1983, 35:284-288.
63. Cranney A., Tugwell P. The use of Neoral in rheumatoid arthritis. New Emer Ther Rheumatoid Arthritis 1998, 24(3):479-488.
64. Cron R.Q. HIV-1, NFAT, and cyclosporin: immunosuppression for the immunosuppressed?. DNA Cell Biol 2001, 20(12):761-767.
65. de Groen P.C., Aksamit A.J., Rakela J., Forbes G.S., Krom R.A.F. Central nervous system toxicity after liver transplantation. New Eng J Med 1987, 317:861-866.
66. Debray D., Maggiore G., Girardet J.P., Mallet E., Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999, 135(1):111-114.
67. Demain A.L. Small bugs, big business: the economic power of the microbe. Biotechnol Adv 2000, 18:499-514.
68. Dittomann J., Wenger R.M., Kleinkauf H., Lawen A. Mechanism of cyclosporin A biosynthesis. Evidence for synthesis via a single linear undecapeptide precursor. J Biol Chem 1994, 269(4):2841-2846.
69. Dobson S., May T., Berriman M., Del Vecchio C., Fairlamb A.H., Chakrabarti D., et al. Characterization of protein Ser/Thr phosphatases of the malaria parasite, Plasmodium falciparum: inhibition of the parasitic calcineurin by cyclophilin-cyclosporin complex. Mol Biochem Parisitol 1999, 99:167-181.
70. Donnenfeld E., Pflugfelder S.C. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 2009, 54:321-338.
71. Dreyfuss M., Harri E., Hofmann H. Cyclosporin A and C: new metabolites from Trichoderma polysporum (Link ex Pers.) Rifai. Eur J Appl Microbiol 1976, 3(2):125-133.
72. Eckstein L.A., Van Quill K.R., Bui S.K., Uusitalo M.S., O'Brien J.M. Cyclosporin A inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells. Invest Ophthalmol Vis Sci 2005, 46:782-790.
73. El Enshasy H.E., Abdel Fattah Y., Atta A., Anwar M., Omar H., Abou S.E., et al. Kinetics of cell growth and cyclosporin A production by Tolypocladium inflatum when scaling up from shake flask to bioreactor. J Microbiol Biotechnol 2008, 18(1):128-134.
74. El-Refai N.A., Abd-Elsalam I.S., Sallam L.A. Kinetic studies on the growth and cyclosporin A production by a local isolate of Fusarium oxysporum. NRC. Acta Pharm Turcica 2004, 46:197-204.
75. Evans D.A., Weber A.E. Asymmetric glycine enolate aldol reactions: synthesis of cyclosporin's unusual amino acid, MeBmt. J Am Chem Soc 1986, 108(21):6757-6761.
76. Evans D.J., Cullinan P., Geddes D.M., Walters E.H., Milan S.J., Jones P. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2000, 4. Article No CD002993.
77. Evers M., Barrière J.-C., Bashiardes G., Bousseau A., Carry J.-C., Dereu N., et al. Synthesis of non-immunosuppressive cyclophilin-binding cyclosporin A derivatives as potential anti-HIV-1 drugs. Bioorg Med Chem Lett 2003, 13(24):4415-4419.
78. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993, 24(6):472-495.
79. Felipe C.R., Park S.I., Pinheiro-Machado P.G., Garcia R., Casarini D.E., Moreira S., et al. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. Fundam Clin Pharmacol 2009, 23(5):625-631.
80. Ferguson R.M., Fidelus-Gort R. Cyclosporine biological activity and clinical application. Cyclosporin A 1983, 134-140. Grune and Stratton Inc. B. Kahan (Ed.).
81. Finzi A.F., Ippolito F., Panconesi E., Giannotti B., Rebora A. A Cyclosporin therapy in psoriasis: recommendations for treatment. Dermatology 1993, 187(1):38-40.
82. Fischer G., Bang H. The refolding of urea-denatured ribonuclease A is catalyzed by peptidyl-prolyl cis-trans isomerase. Biochim Biophys Acta 1985, 828(1):39-42.
83. Fischer G., Wittmann-Liebold B., Lang K., Kiefhaber T., Schmid F.X. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 1989, 337:476-478.
84. Foster B.C., Coutts R.T., Pasutto F.M., Dossetor J.B. Production of cyclosporin A by carrageenan-immobilized Tolypocladium inflatum in an airlift reactor with external loop. Biotechnol Lett 1983, 5(10):693-696.
85. Freeman D.J. Pharmacology and pharmacokinetics of cyclosporine. Clin Biochem 1991, 24:9-14.
86. Gallego M.J., Garcia Villalon A.L., Lopez Farre A.J., Garcia J.L., Garron M.P., Casado S., et al. Mechanisms of the endothelial toxicity of cyclosporin A. Role of nitric oxide, cGMP, and Ca2+. Circ Res 1994, 74:477-484.
87. Galpin I.J., Mohammed A.K.A., Patel A. Synthetic studies of cyclosporine analogues. Tetrahydron 1988, 44(6):1783-1794.
88. Gams W. Tolypocladium eine Hyphomycetengattung mit geschwollenen Phialiden. Persoonia 1971, 6(2):185-191.
89. George N., Kuppusamy M., Balaraman K. Optimization of high performance liquid chromatographic conditions for the determination of cyclosporins A, B and C in fermentation samples. J Chromatogr 1992, 604:285-289.
90. Gharavi M., Najafi R.B., Kloobandi A. Mutation of Tolypocladium inflatum (DSM 915) by UV radiation for higher production of cyclosporin A. Saudi Pharm J 2004, 12(2-3):112-115.
91. Gong Y., Christensen E., Gluud C. Cyclosporin A for primary biliary cirrhosis. Cochrane Database Syst Rev 2007, 3. Article No. CD005526.
92. Goto T, Kino T, Okuhara M, Tanaka H, Tsurumi Y, Takase S. Production of cyclosporin A and/or C with a strain of NECTRIA. 1995;US Patent 5447854.
93. Goto K., Watashi K., Inoue D., Hijikata M., Shimotohno K. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci 2009, 100(10):1943-1950.
94. Gratwohl A., Forster I., Speck B. Histoincompatible skin and marrow grafts in rabbits on cyclosporin a. Transplantation 1982, 33:361-364.
95. Grau G.E., Gretener D., Lambert P.H. Prevention of murine cerebral malaria by low-dose cyclosporin A. Immunology 1987, 61:521-525.
96. Gulati A.K., Zalewski A.A. Muscle allograft survival after cyclosporin A immunosuppression. Exp Neurol 1982, 77:378-385.
97. Halloran P.F. Rethinking immunosuppression in terms of the redundant and nonredundant steps in the immune response. Transplant Proc 1996, 28(suppl 1):11-18.
98. Hamawy M.M., Knechtle S.J. An overview of the actions of cyclosporine and FK506. Transplant Rev 2003, 17(4):165-171.
99. Handschumacher R.E., Harding M.W., Rice J., Drugge R.J., Speicher D.W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984, 226:544-547.
100. Harding M.W., Handschumacher R.E. Cyclophilin, a primary molecular target for cyclosporine. Structural and functional implications. Transplantation 1988, 46:29S-35S.
101. Harding M.W., Galat A., Uehling D.E., Schreiber S.L. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989, 341:758-760.
102. Hegedus D.D., Khachatourians G.G. Identification of molecular variants in mitochondrial DNAs of members of the genera Beauveria, Verticillium, Paecilomyces, Tolypocladium, and Metarhizium. Appl Environ Microbiol 1993, 59:4283-4288.
103. Hermann M., Asberg A., Reubsaet J.L., Sather S., Berg K.J., Christensen H. Intake of grapefruit juice alters the metabolic pattern of cyclosporin A in renal transplant recipients. Int J Clin Pharmacol Ther 2002, 40(10):451-456.
104. High K.P., Handschumacher R.E. Immunity, microbial pathogens and immunophilins: finding the keys, now where are the locks?. Infect Agents Dis 1995, 1:121-135.
105. Hingorani M., Calder V.L., Buckley R.J., Lightman S. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest Ophthalmol Vis Sci 1999, 40:392-399.
106. Hoffmann K., Schneider-Scherzer E., Kleinkauf H., Zocher R. Purification and characterization of eucaryotic alanine racemase acting as key enzyme in cyclosporin biosynthesis. J Biol Chem 1994, 269:12710-12714.
107. Hom M.M. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients. Eye Contact Lens 2006, 32:109-111.
108. Hoppert M., Gentzsch C., Schörgendorfer K. Structure and localization of cyclosporin synthetase, the key enzyme of cyclosporin biosynthesis in Tolypocladium inflatum. Arch Microbiol 2001, 176:285-293.
109. Hunter P.A., Wilhelmus K.R., Rice N.S.C., Jones B.R. Cyclosporin A applied topically to the recipient eye inhibits corneal graft rejection. Clin Exper Immunol 1981, 45:173-177.
110. Husek A. High performance liquid chromatographic analysis of cyclosporin A and its oral solutions. J Chromatogr A 1997, 759(1-2):217-224.
111. Husi H., Schörgendorfer K., Stempfer G., Taylor P., Wakinshaw M.D. Prediction of substrate-specific pockets in cyclosporine synthetase. FEBS Lett 1997, 414:532-536.
112. IARC Pharmaceutical drugs. IARC monographs on the evaluation of carcinogenic risk of chemicals to humans 1990, vol. 50:415. International Agency for Research on Cancer, Lyon, France.
113. Ibrahim S.A., Abd-Elnasser, Kattab A. Enhancement of cyclosporin a production by Tolypocladium inflatum using some mutagenic agents. Acta Pharm Sci 2009, 51(1):87-92.
114. Inoue K., Sekiyama K., Yamada M., Watanabe T., Yasuda H., Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003, 38:567-572.
115. Isaac C.C., Jones A., Pickard M.A. Production of cyclosporine A by Tolypocladium niveum strains. Antimicrob Agents Chemother 1990, 34:121-127.
116. Ismaiel A.A., El-Sayed A.E., Mahmoud A.A. Some optimal culture conditions for production of cyclosporin A by Fusarium roseum. Braz J Microbiol 2010, 41:1112-1123.
117. Ismailos G., Repas C., Dressman J.B., Macheras P. Unusual solubility behaviour of cyclosporin A in aqueous media. J Pharm Pharmacol 1991, 43:287-289.
118. Ismailos G., Reppas C., Macheras P. Enhancement of cyclosporin A solubility by d-alphatocopheryl-polyethylene-glycol-1000 succinate (TPGS). Eur J Pharm Sci 1994, 1(5):269-271.
119. Jegorov A., Matha V., Weiser J. Production of cyclosporins by entomopathogenic fungi. Microbios Lett 1990, 45:65-69.
120. Jegorov A., Matha V., Husak M., Kratochvil B., Stuchlik J., Sedmera P., et al. Iron uptake system of some members of the genus Tolypocladium: crystal structure of the ligand and its iron (III) complex. J Chem Soc Dalton Trans 1993, 1:1287-1294.
121. Jegorov A., Matha V., Sedmera P., Havlicek V., Stuchlik J., Seidel P., et al. Cyclosporins from Tolypocladium terricola. Phytochemistry 1995, 38:403-407.
122. Kadlec Z., Šimek P., Heydová A., Jegorov A., Matha V., Landa Z., et al. Chemotaxonomic discrimination among the fungal genera Tolypocladium, Beauveria and Paecilomyces. Biochem Syst Ecol 1994, 22(8):803-806.
123. Cyclosporin: biological activity and clinical applications 1984, Crune & Straton Inc., Orlando. B.D. Kahan (Ed.).
124. Kahan B.D. lndividualisation of cyclosporine therapy using pharma cokinetic and pharmacodynamic parameter. Transplantation 1986, 40:457-476.
125. Kallen J., Mikol V., Quesniaux V.F.J., Walkinshaw M.D., Schneider-Scherzer E.S., Schorgendorfer K., et al. Cyclosporins: recent developments in biosynthesis, pharmacology and biology, and clinical applications. Biotechnology, a Multivolume Comprehensive Treatise 1997, Vol. 7:535-591. VCH Verlagsgesellschaft, Weinheim. H.J. Rehm, G. Reed, A. Puhler, H. vonDohren (Eds.).
126. Katz E. Controlled biosynthesis of actinomycins. Cancer Chemother Rep 1974, 58:83-91.
127. Kempken F., Schreiner C., Schörgendorfer K., Kück U. A unique repeated DNA sequence in the cyclosporin-producing strain of Tolypocladium inflatum (ATCC 34921). Exper Mycol 1995, 19(4):305-313.
128. Khanna A., Kapur S., Sharma V., Li B., Suthanthiran M. In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine. Transplantation 1997, 63:1037-1039.
129. Kleinkauf H., Koischwitz H. Multifunctional proteins 1978, Wiley, New York. H. Bissanger, E. Schmin-Ckeott (Eds.).
130. Kleinkauf H., von Döhren H. Biosynthesis of cyclosporins and related peptides. Fungal biotechnology 1997, 147-161. Chapman & Hall, Weinheim. T. Anke (Ed.).
131. Kleinkauf H., von Döhren H. Comprehensive natural products chemistry 1999, vol. 1:533. Pergamon/Elsevier, New York.
132. Klintmalm G.B., Iwatsuki S., Starzl T.E. Cyclosporine A hepatotoxicity in 66 renal allograft recipients. Transplantation 1981, 32(6):488-489.
133. Kobel H., Traber R. Directed biosynthesis of cyclosporins. Eur J Appl Microbiol Biotechnol 1982, 14:237-240.
134. Kobel H., Loosli H.R., Voges R. Contribution to knowledge of the biosynthesis of cyclosporin A. Experientia 1983, 39:873-876.
135. Kovarik J.M., Mueller E.A., Gerbeau C., Tarral A., Francheteau P., Guerret M. Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis. J Clin Pharmacol 1997, 37:336-343.
136. Krasnoff S.B., Gupta S., Leger St R.J., Renwick J.A.A., Roberts D.W. Antifungal and insecticidal properties of the efrapeptins: metabolites of the fungus Tolypocladium niveum. J Invertebr Pathol 1991, 58:180-188.
137. Kreuzig F. High-speed liquid chromatography with conventional instruments for the determination of cyclosporin A, B, C and D in fermentation broth. J Chromatogr 1984, 290:181-186.
138. Kutlay S., Savas S., Yalcin P., Ataman S., Ergin S. Central nervous system toxicity of cyclosporin A treatment in rheumatoid arthritis. Br J Rheumatol 1997, 36:397-399.
139. Lawen A., Traber R. Substrate specificities of cyclosporin synthetase and peptolide SDZ 214-103 synthetase. Comparison of the substrate specificities of the related multifunctional polypeptides. J Biol Chem 1993, 268:20452-20465.
140. Lawen A., Zocher R. Cyclosporin synthetase: the most complex peptide synthesizing multienzyme polypeptide so far described. J Biol Chem 1990, 265(19):11355-11360.
141. Lawen A., Traber R., Geyl D., Zocher R., Kleinkauf H. Cell-free synthesis of new cyclosporins. J Antibiot 1989, 42:1283-1289.
142. Lawen A., Traber R., Geyl D. In vitro biosynthesis of [Thr2, Leu5, D-Hiv8, Leu10] cyclosporin, a cyclosporin-related immunosuppressive peptolide. Biomed Biochim Acta 1991, 50:S260-S263.
143. Lawen A., Traber R., Geyl D. In vitro biosynthesis of [Thr2, Leu5, D-Hiv8, Leu10] cyclosporin, a cyclosporin-related peptolide, with immunosuppressive activity by a multienzyme polypeptide. J Biol Chem 1991, 266:15567-15570.
144. Lawen A., Traber R., Reuille R., Ponelle M. In vitro biosynthesis of ring-extended cyclosporins. J Biochem 1994, 300:395-399.
145. Ledermann J.A., Begent R.H.J., Bagshawe K.D., Riggs S.J., Searle F., Glaser M.G., et al. Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin-A. Br J Cancer 1988, 58:656-657.
146. Lee T.H. Development of immobilized cell separator and its application to immobilized continuous process for the production of cyclosporin A. Korean J Appl Microbiol Biotechnol 1996, 24(6):717-725.
147. Lee J., Agathos S.N. Effect of amino acids on the production of cyclosporin A by Tolypocladium inflatum. Biotechnol Lett 1989, 11:77-82.
148. Lee J., Agathos S.N. Dynamics of l-valine in relation to the production of cyclosporin A by Tolypocladium inflatum. Appl Microbiol Biotechnol 1991, 34(4):513-517.
149. Lee S.S., Kim H., Wang N.S., Bungay P.M., Gilger B.C., Yuan P., et al. A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection. Invest Ophthalmol Vis Sci 2007, 48:2023-2029.
150. Lee M.J., Lee H.N., Han K., Kim E.S. Spore inoculum optimization to maximize cyclosporin A production in Tolypocladium niveum. J Microbiol Biotechnol 2008, 18(5):913-917.
151. Lee M.J., Duong C.T.P., Han K., Kim E.S. Combination strategy to increase cyclosporine A productivity by Tolypocladium niveum using random mutagenesis and protoplast transformation. J Microbiol Biotechnol 2009, 19(9):869-872.
152. Leitner, E., Schneider, E., Schoergendorfer, K., Weber, G. Cyclosporin synthetase. 1998; US Patent 5827706.
153. Lémann M., Gerard de La Valussière F., Carbonnel F., Bouhnik Y., Bonnet J., Allez M., et al. Intravenous cyclosporine for perianal Crohn's disease (CD). Gastroenterology 1998, 114(1):A1020.
154. Leung P.H., Zhang Q.X., Wu J.Y. Mycelium cultivation, chemical composition and antitumour activity of a Tolypocladium sp. fungus isolated from wild Cordyceps sinensis. J Appl Microbiol 2006, 101(2):275-283.
155. Li G.-Y., Liu J.-Z., Zhang B., Wang L.-X., Wang C.-B., Chen S.-G. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia. Biomed Pharmacother 2009, 63(8):566-570.
156. Luban J., Bossolt K.L., Franke E.K., Kalpana G.V., Goff S.P. Human immunodeficiency virus type I gag protein binds to cyclophilins A and B. Cell 1993, 73:1067-1078.
157. Ly M., Margaritis A. Effect of temperature on the extraction kinetics and diffusivity of cyclosporin A in the fungus Tolypocladium inflatum. Biotechnol Bioeng 2007, 96(5):945-955.
158. Ly M., Margaritis A., Jajuee B. Effect of solvent concentration on the extraction kinetics and diffusivity of cyclosporin A in the fungus Tolypocladium inflatum. Biotechnol Bioeng 2007, 96(1):67-79.
159. Mack D.G., McLeod R. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother 1984, 26:26-30.
160. Malaekeh-Nikouei B., Nassirli H., Davies N. Enhancement of cyclosporine aqueous solubility using α- and hydroxypropyl β-cyclodextrin mixtures. J Incl Phenom Macro Chem 2007, 59(3-4):245-250.
161. Marahiel M.A., Stachelhaus T., Mootz H.D. Modular peptide synthetases involved in non-ribosomal synthesis. Chem Rev 1997, 97:2651-2673.
162. Margaritis A., Chahal P.S. Development of a fructose based medium for biosynthesis of cyclosporine A by Beauveria nivea. Biotechnol Lett 1989, 11:765-768.
163. Marks A.R. Cellular functions of immunophilins. Physiol Rev 1996, 76:631-649.
164. McCabe R.E., Remington J.S., Araujo F.G. In vivo and in vitro effects of cyciosporin A on Trvpaplusomu cruzi. Am J Trop Med Hyg 1985, 34:861-865.
165. Mcintosh L.C., Thomson A.W. Activity of the mononuclear phagocyte system in cyclosporin A-treated mice. Transplantation 1980, 30:384-385.
166. McNeil B., Harvey L. Viscous fermentation products. Crit Rev Biotechnol 1993, 13:275-304.
167. Meier C., Stey C., Brack T., Maggiorini M., Risti B., Krahenbuhl S. Rhabdomyolyse bei mit simvastatin und cyclosporin behandelten patienten: rolle der aktivität des cytochrom-P450-enzymsystems der leber. Schweiz Med Wochenschr 1995, 125:1342-1346.
168. Meissner U., Jüttner S., Röllinghoff M., Gessner A. Cyclosporin A-mediated killing of Leishmania major by macrophages is independent of reactive nitrogen and endogenous TNF-α and is not inhibited by IL-10 and 13. Parasitol Res 2003, 89(3):221-227.
169. Meyer-Lehnert H., Schrier R.W. Potential mechanism of cyclosporine A-induced vascular smooth muscle contraction. Hypertension 1989, 13:352-360.
170. Mugnai L., Bridge P.D., Evans H.C. A chemotaxonomic evaluation of the genus Beauveia. Mycol Res 1989, 92:199-209.
171. Munro G.H., Mclaren D.J. Toxicity of cyclosporin A (CsA) against developmental stages of Schistosoma munsoni in mice. Parasitology 1990, 100:29-34.
172. Mutter, M., Wenger, R., Guichou, J.-F., Keller, M., Ruckle, T., Woehr, T. Cyclosporin derivatives and method for the production of said derivatives. 2004; US Patent 6790935.
173. Nakagawa M., Sakamoto N., Enomoto N., Tanabe Y., Kanazawa N., Koyama T., et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004, 313:42-47.
174. Nakagawa M., Sakamoto N., Tanabe Y., Koyama T., Itsui Y., Takeda Y., et al. Suppression of hepatitis c virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005, 129:1031-1041.
175. Nakajima H., Hamasaki T., Nishimura K., Kimura Y., Udagawa S., Sato S. Isolation of 2-acetylamino-3-hydroxy-4-methyl-oct-6- enoic acid, a derivative of the 'C9 amino acid' residue of cyclosporins, produced by the fungus Neocosmospora vasinfecta E. F. Smith. Agri Biol Chem 1988, 52:1621-1623.
176. Nakajima H., Hamasaki T., Tanaka K., Kimura Y., Udagawa S., Horie Y. Production of cyclosporin by fungi belonging to the genus Neocosmospora. Agric Biol Chem 1989, 53(8):2291-2292.
177. Niaudet P., Habib R. Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 1994, 5:1049-1056.
178. Nicholls S., Domizio P., Williams C.B., Dawnay A., Braegger C.P., MacDonald T.T., et al. Cyclosporin as initial treatment for Crohn's disease. Arch Dis Childhood 1994, 71(3):243-247.
179. Nickell S.P., Scheibel A., Cobe G.A. Inhibition by cyclosporin A of rodent malaria in vivo and human malaria in vitro. Infect Immun 1982, 37:1093-1100.
180. Nisha A.K., Ramasamy K. Cyclosporin production in various solid substrate media by Tolypocladium inflatum ATCC 34921. Biotechnology 2008, 7(2):357-359.
181. Nisha A.K., Meinnanalakshmi S., Ramasamy K. Comparative effect of amino acids in the production of cyclosporine A by solid and submerged fermentations. Biotechnology 2008, 7(2):205-208.
182. Norin A.J., Emerson E.E., Kamholz S.L., Pinsker K.L., Montefusco C.M., Matas A.J., et al. Cyclosporin A as the initial immunosuppressive agent for canine lung transplantation: short and long-term assessment of rejection phenomena. Transplantation 1982, 34:372-375.
183. Nussbaum E.S., Maxwell R.E., Bitterman P.B., Hertz M.I., Bula W., Latchaw R.E. Cyclosporine A toxicity with acute cerebellar edema and brainstem compression. J Neurosurg 1995, 82:1068-1070.
184. Offenzeller M., Su Z., Santer G., Moser H., Traber R., Memmert K., et al. Biosynthesis of the unusual amino acid (4R)-4-[(E)-2-butenyl]-4-methyl-L-threonine of cyclosporine A. Identification of 3(R)-hydroxy-4(R)-methyl-6(E)-octenoic acid as a key intermediate by enzymatic in vitro synthesis and by in vivo labeling techniques. J Biol Chem 1993, 268:26127-26134.
185. Page A.P., Kumar S., Carlow C.K.S. Parasite cyclophilins and antiparasite activity of cyclosporin A. Parasitol Today 1995, 11:385-388.
186. Palmer B.F., Toto R.D. Severe neurologic toxicity induced by cyclosporine A in three renal transplant patients. Am J Kidney Dis 1991, XVIII:116-121.
187. Pandey A., Soccol C.R., Nigam P., Soccol V.T. Biotechnological potential of agro-industrial residues. I: sugarcane bagasse. Bioresour Technol 2000, 74:69-80.
188. Peeters H., Zocher R., Kleinkauf H. Synthesis of beauvericin by a multifunctional enzyme. J Antibiot 1988, 41:352-359.
189. Perry H.D., Doshi-Carnevale S., Donnenfeld E.D., Solomon R., Biser S.A., Bloom A.H. Efficacy of commercially available topical cyclosporin A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006, 25(2):171-175.
190. Petcher T.J., Weber H.P., Rüegger A. Crystal and molecular structure of an iodo-derivative of the cyclic undecapeptide cyclosporin A. Helv Chimi Acta 1976, 59(5):1480-1489.
191. Pirsch J.D., Miller J., Deierhoi M.H., Vincenti F., Filo R.S. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997, 63:977-983.
192. Porwit A., Panayotides P., Mansson E., Ösby E., Hast R., Reizenstein P. Cyclosporine A treatment in four cases of aplastic anemia. Ann Hematol 1987, 54(2):73-78.
193. Prashar Y., Khanna A., Sehajpal P., Sharma V.K., Suthanthiran M. Stimulation of transforming growth factor-β1 transcription by cyclosporine. FEBS Lett 1995, 358:109-112.
194. Rakotonirainy M.S., Dutertre M., Brygoo Y., Riva G. rRNA sequence comparison of Beauveria bassiana, Tolypocladium cylindrosporum, and Tolypocladium extinguens. J Invertebr Pathol 1991, 57:17-22.
195. Ramana Murthy M.V., Karanth N.G., Rao R.K.S.M.S. Biochemical engineering aspects of solid state fermentation. Adv Appl Microbiol 1993, 39:99-149.
196. Ramana Murthy M.V., Mohan E.V.S., Sadhukhan A.K. Cyclosporin A production by Tolypocladium inflatum using solid state fermentation. Process Biochem 1999, 34:269-280.
197. Range B.G., Keevil D.P., Tierney, Cooper D.P., Morris M.R. Rapid liquid chromatography-tandem mass spectrometry method for routine analysis of Cyclosporin A over an extended concentration. Clin Chem 2002, 48(1):69-76.
198. Rehacek Z. The cyclosporins. Folia Microbiol 1995, 40:68-88.
199. Rehacek Z., De-xiu Z. The biochemistry of cyclosporin formation: a review. Process Biochem 1991, 26:157-166.
200. Reitz B.A., Stinson E.B. Cardiac transplantation. JAMA 1982, 248:1225-1227.
201. Rifai M.A. A revision of the genus Trichoderma. Mycol Papers 1969, 116:1-56.
202. Rosenthaler J., Keller H.P. Comment on cyclosporine assay techniques: an attempt for recommendations. Transplant Proc 1990, 22:1160-1165.
203. Rubin M., Rao S.N. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther 2006, 22(1):47-53.
204. Rudat, W.R., Bormann, E.J., Arnold, G. Process for making and isolating cyclosporin A by fermentation. 1993; US Patent 5256547.
205. Saini M., Potash M.J. Novel activities of cyclophilin A and cyclosporin A during HIV-1 infection of primary lymphocytes and macrophages. J Immunol 2006, 177:443-449.
206. Sallam L.A.R., El-Refai A.H., Hamdi A.A., El-Minofi A.H., Abd-Elsalam S.I. Role of some fermentation parameters on cyclosporin A production by a new isolate of A. terreus. J Gen Appl Microbiol 2003, 49:321-328.
207. Sallam L.A.R., El-Refai A.H., Hamdi A.A., El-Minofi A.H., Abd-Elsalam S.I. Studies on the application of immobilization technique for the production of cyclosporin A by a local strain of Aspergillus terreus. J Gen Appl Microbiol 2005, 51:143-149.
208. Salm P., Taylor P.J., Lynch S.V., Warnholtz C.R., Pillans P.I. A rapid HPLC-mass spectrometry cyclosporin method suitable for current monitoring practices. Clin Biochem 2005, 38(7):667-673.
209. Salomão M.Q., Ambrósio R., Wilson S.E. Dry eye associated with laser in situ keratomileusis: mechanical microkeratome versus femtosecond laser. J Cataract Refract Surg 2009, 35(10):1756-1760.
210. Samson R.A., Soares G.G. Entomopathogenic species of the hyphomycete genus Tolypocladium. J Invertebr Pathol 1984, 43:133-139.
211. Sawai K., Okuno T., Tereda Y., Harada Y., Wawamura K., Sasaki H., et al. Isolation and properties of two antifungal substances from Fusarium solani. Agric Biol Chem 1981, 45:1223-1228.
212. Schechter B.A., Katz R.S., Friedman L.S. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther 2009, 26(6):651-659.
213. Schindler R. Cyclosporin in autoimmune diseases 1985, Springer-Verlag, Berlin.
214. Schmidt B., Riesner D., Lawen A. Cyclosporin synthetase is a 14 MDa multienzyme polypeptide. Re-evaluation of the molecular masses of various peptide synthetases. FEBS Lett 1992, 307:355-360.
215. Schorgendorfer, Stempfer K., Husi G., Walkinshaw H. Method of altering the domains of cyclosporin synthetase to give a modified cyclosporine synthetase 1999, WO 99102659.
216. Schreiber S.L. Immunophilin-sensitive protein phosphatase action in cell signaling pathways. Cell 1992, 70:365-368.
217. Schwarz A., Offermann G., Keller F., Bennhold I., L'age-Stehr J., Krause P.H., et al. The effect of cyclosporin on the progression of human immunodeficiency virus type I infection transmitted by transplantation - data on four cases and review of the literature. Transplantation 1993, 55:95-103.
218. Sekar C. Studies on the immobilization of Tolypocladium sp. for the production of cyclosporine A and its mechanism of biosynthesis. 1991; Ph.D. Thesis, Pondicherry University, India.
219. Sekar C., Balaraman K. Effect of precursor amino acids on the production of cyclosporin A by solid state fermentation. Indian J Microbiol 1996, 36(4):231-232.
220. Sekar C., Balaraman K. Immobilization of the fungus, Tolypocladium sp. for the production of cyclosporin A. Bioproc Eng 1998, 19:281-283.
221. Sekar C., Balaraman K. Optimization studies on the production of cyclosporin A by solid state fermentation. Bioproc Eng 1998, 18:293-296.
222. Sekar C., Rajasekar V.W., Balaraman K. Production of cyclosporin A by solid state fermentation. Bioproc Eng 1997, 17:257-259.
223. Shin G.T., Khanna A., Ding R., Sharma V.K., Lagman M., Li B., et al. In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation 1998, 65:313-318.
224. Shulman N., Winters M. A review of HIV-1 resistance to the nucleoside and nucleotide inhibitors. Curr Drug Targets Infect Disord 2003, 3:273-281.
225. Sigma Material safety data sheet. Cyclosporin A 2000, Sigma Chemical Co., http://msdssolutions.com/and search cyclosporin A.
226. Simpson J., Zhang Q., Ozaeta P., Aboleneen H. A specific method for the measurement of cyclosporin A in human whole blood by liquid chromatography-tandem mass spectrometry. Ther Drug Monit 1998, 20:294-300.
227. Somasundaram C., Ng M.L., Sinniah R. An in vivo study on the effect of the immunosuppressant drug cyclosporin in malaria-infected mice. Transact Roy Soc Trop Med Hyg 1989, 83:71.
228. Sotnikova I.V., Telesnina G.N., Krakhmaleva I.N., Sazykin Iu.O., Navashin S.M. High molecular polyphosphates and pyrophosphate in cyclosporin producing Tolypocladium sp. and their role in the processes of growth and antibiotic synthesis. Antibiot Khimioter 1990, 35(8):9-11.
229. Sowden J.M., Berth-Jones J., Ross J.S., Motley R.J., Marks R., Finlay A.Y., et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991, 338:137-140.
230. Starzl T.E., Iwatsuk S., Van Thiel D.H., Gartner J.C., Zitelli B.J., Malatack J.J., et al. Evolution of liver transplantation. Hepatology 1982, 2:614-636.
231. Stimberg N., Walz M., Schorgendorfer K., Kuck U. Electrophoretic karyotyping from Tolypocladium inflatum and six related strains allows differentiation of morphologically similar species. Appl Microbiol Biotechnol 1992, 37:485-489.
232. Strong B., Farley W., Stern M.E., Pflugfelder S.C. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea 2005, 24:80-85.
233. Survase S.A., Shaligram N.S., Pansuriya R.C., Annapure U.S., Singhal R.S. A novel medium for the enhanced production of cyclosporin A by Tolypocladium inflatum MTCC 557 using solid state fermentation. J Microbiol Biotechnol 2009, 19(5):462-467.
234. Survase S.A., Annapure U.S., Singhal R.S. Statistical optimization for improved production of cyclosporin A in solid-state fermentation. J Microbiol Biotechnol 2009, 19(11):1385-1392.
235. Survase S.A., Annapure U.S., Singhal R.S. Use of coconut coir fibers as an inert solid support for the production of cyclosporin A using Tolypocladium inflatum MTCC 557. Biotechnol Biopro Eng 2009, 14(6):769-774.
236. Survase S.A., Annapure U.S., Singhal R.S. Statistical optimization of cyclosporin A production on a semi-synthetic medium using Tolypocladium inflatum MTCC 557. Glob J Biotechnol Biochem 2009, 4(2):184-192.
237. Survase S.A., Annapure U.S., Singhal R.S. Gellan gum as immobilization matrix for production of cyclosporin A. J Microbiol Biotechnol 2010, 20(7):1086-1091.
238. Survase S.A., Annapure U.S., Singhal R.S. The effect of medium supplementation with a second carbon source and amino acids for enhanced production of cyclosporin A. Curr Trends Biotechnol Pharm 2010, 4(3):764-773.
239. Sweet P., Chan P.K., Slater L.M. Cyclosporin A and verapamil enhancement of daunorubicin-produced nucleolar protein B23 translocation in daunorubicin-resistant and -sensitive human and murine tumor cells. Cancer Res 1989, 49:677-680.
240. Swidinsky K. The regulation of secondary metabolism from Tolypocladium inflafum: a study on strain improvement in cyclosporin A productivity and its relation to growth and glucose metabolism. 1998; Masters Thesis, Department of Microbiology, University of Manitoba, Winnipeg, Manitoba.
241. Szanya T, Hanak L, Strbka G, Nagy E, Melczer I, Deak G, et al. Process for the purification of cyclosporin A. 1995; US Patent 5382655.
242. Takahashi N., Hayano T., Suzuki M. Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989, 337:473-475.
243. Tang-Liu D.D., Acheampong A. Ocular pharmacokinetics and safety of cyclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet 2005, 44:247-261.
244. Thali M. Cyclosporins: immunosuppressive drugs with anti-HIV-1 activity. Mol Med Today 1995, 1(6):287-291.
245. Thali M., Bukovsky A., Kondo E., Rosenwirth B., Walsh C.T., Sodroski J., et al. Functional association of cyclophilin A with HIV-1 virions. Nature 1994, 372:363-365.
246. Therwil E, Ruegger A. Organic compounds. 1978; US Patent 411118.
247. Thomson C.B., June C.H., Sullivan K.M., Thomas E.D. Association between cyclosporine neurotoxicity and hypomagnesemia. Lancet 1984, 2:1116-1120.
248. Todorova S.I., Cote J.C., Coderre D. Distinction between Beauveria and Tolypocladium by carbohydrate utilization. Mycol Res 1998, 102(1):81-87.
249. Traber A., Kuhn M., Loosli H.R., Pache W., Wartburg A. Neue cyclopeptide aus Trichoderma polysporum (LINK EX PERS.) Rifai: die cyclosporine B, D und E. Helv Chim Acta 1977, 60(5):1568-1578.
250. Traber A., Kuhn M., Rugger A., Lichti H., Loosli H.R., Wartburg A. Die struktur von cyclosporin C. Helv Chim Acta 1977, 60(4):1247-1255.
251. Traber A., Loosli H.R., Hoffmann H., Wartburg A. Isolierung und strukturermittlung der neuen cyclosporine E, F, G, H und I. Helv Chim Acta 1982, 65(5):1655-1677.
252. Traber R., Hoffmann H., Kobel H. Cyclosporins - new analogues by precursor directed biosynthesis. J Antibiot 1989, 42:591-597.
253. Tredger J.M., Roberts N., Sherwood R., Higgins G., Keating J. Comparison of five cyclosporin immunoassays with HPLC. Clin Chem Lab Med 2000, 38(11):1205-1207.
254. Tsantrizos Y.S., Pischos S., Sauriol F. Structural assignment of the peptide antibiotic LP237-F8, a metabolite of Tolypocladium geodes. J Org Chem 1996, 61:2118-2121.
255. Twentyman P.R. A possible role of cyclosporins in cancer chemotherapy. Anticancer Res 1988, 8:985-993.
256. Twentyman P.R., Reeve J.G., Koch G., Wright K.A. Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin). Br J Cancer 1990, 62:89-95.
257. Van Bekkum D.W., Knaan S., Zurcher C. Effects of cyclosporin A on experimental graft-versus-host disease in rodents. Transplant Proc 1980, 12:278-282.
258. Van Buren C.T., Flechner S.M., Kerman R.H., Vaughn W., Kahan B.D. Cyclosporine improves outcome in high risk cadaveric renal allograft recipients. Transplant Proc 1984, 16:1162-1166.
259. Van de Vrie W., Gheuens E.E., Durante N.M., De Bruijn E.A., Marquet R.L., Van Oosterom A.T., et al. In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour. J Cancer Res Clin Oncol 1993, 119(10):609-614.
260. Van de Vrie W., Marquet R.L., Eggermont A.M.M. Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour. J Cancer Res Clin Oncol 1997, 123(1):21-24.
261. Van Joost T., Heule F., van den Korstanje M., Broek M.J., Stenveld H.J., van Vloten W.A. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 1994, 130:634-640.
262. Vayuvegula B., Slater L., Meador J., Gupta S. Correction of altered plasma membrane potentials. Cancer Chemother Pharmacol 1988, 22:163-168.
263. Velkov T., Singaretnam L.G., Lawen A. An improved purification procedure for cyclosporin synthetase. Protein Expr Purif 2006, 45(2):275-287.
264. Vogel M., Voigt E., Michaelis H.-C., Sudhop T., Wolff M., Türler A., et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transplant 2004, 10:939-944.
265. von Arx J.A. Tolypocladium, a synonym of Beauveria. Mycotaxon 1986, 25:153-158.
266. von Dohren H. Biochemistry and general genetics of nonribosomal peptide synthetases in fungi. Adv Biochem Eng/Biotechnol 2004, 88:217-264.
267. von Wartburg A., Traber R. Chemistry of the natural cyclosporin metabolites. Prog Allergy 1986, 38:28-45.
268. Wadhwa N.K., Schroeder T.J., Pesce A.J., Myre S.A., Clardy C.W., First M.R. Cyclosporine drug interactions: a review. Ther Drug Monitor 1987, 9(4):399-406.
269. Wastling J.M., Gerrard D., Walker J., Chappall L.H. Action of cyclosporin A on the tapeworm Hymenolepir diminuta in mice. Parasitology 1990, 101:465-472.
270. Watashi K., Hijikata M., Hosaka M., Yamaji M., Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003, 38:1282-1288.
271. Watashi K., Ishii N., Hijikata M., Inoue D., Murata T., Miyanari Y., et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005, 19:111-122.
272. Watt D.J., Partridge T.A., Sloper J.C. Cyclosporin A as a means of preventing rejection of skeletal muscle allografts in mice. Transplantation 1981, 31(4):266-271.
273. Weber G., Leitner E. Disruption of the cyclosporin synthetase gene of Tolypocladium niveum. Curr Genetics 1994, 26(5-6):461-467.
274. Weber G., Schörgendorfer K., Schneider-Scherzer E., Leitner E. The peptide synthetase catalyzing cyclosporine production in Tolypocladium niveum is encoded by a giant 458-kilobase open reading frame. Curr Genetics 1994, 26:120-125.
275. Wenger R.M. Cyclosporin A. Biomed J 1982, 3:19-31.
276. Wenger R. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production. 1983; US Patent 4396542.
277. Wiesinger D., Borel J.F. Studies on the mechanism of action of cyclosporin A. Immunobiology 1979, 156(4-5):454-463.
278. Wright D.H., Lake K.D., Bruhn P.S., Emery R.W. Nefazodone and cyclosporine drug-drug interaction. J Heart Lung Transplant 1999, 18(9):913-915.
279. Xiao-xian Z., Guan-rong Q., Xin-dong T., Yuan-rong C. The optimum of fermentation process and observation of the filamentous morphology of Beauveria nivea CA411 producing cyclosporin A. Chin J Antibiot 2009, 34(2):97-99.
280. Yee G.C. Recent advances in cyclosporine pharmacokinetics. Pharmacotherapy 1991, 11(5):130S-134S.
281. Yoon K.C., Heo H., Kang I.S., Lee M.C., Kim K.K., Park S.H., et al. Effect of topical cyclosporin A on herpetic stromal keratitis in a mouse model. Cornea 2008, 27(4):454-460.
282. Zhao D., Beran M., Kozová J., Řeháček Z. Formation of cyclosporins by Tolypocladium inflatum. Folia Microbiol 1991, 36(6):549-556.
283. Zocher R., Keller U., Kleinkauf H. Enniatin synthetase, a novel type of multifunctional enzyme catalyzing depsipeptide synthesis in Fusarium oxysporum. Biochemistry 1982, 21:43-48.
284. Zocher R.N., Madry H., Peeters, Kleinkauf H. Biosynthesis of cyclosporin A. Phytochemistry 1984, 23:549-551.
285. Zocher R., Nihira T., Paul E., Madry N., Peeters H., Kleinkauf H., et al. Biosynthesis of cyclosporin A: partial purification and properties of a multifunctional enzyme from Tolypocladium inflatum. Biochemistry 1986, 25:550-553.
286. Zocher R., Keller U., Lee C., Hoffmann K. A seventeen kilodaltons peptidyl-prolyl cis-trans isomerase of the cyclosporin-producer Tolypocladium inflatum is sensitive to cyclosporin A. J Antibiot 1992, 45:265-268.
287. Zoja C., Furci L., Ghilardi F., Zilio P., Benigni A., Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Investig 1986, 55:455-462.
288. Zwitter M. On the potential role of cyclosporin in the treatment of lymphoproliferative diseases. Leuk Res 1988, 12:243-248.
289. Zylber-Katz E. Multiple drug interactions with cyclosporine in a heart transplant patient. Ann Pharmacother 1995, 29(2):127-131.